A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

NCT05106335 PHASE3 TERMINATED

This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.

Details

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	PHASE3
Status	TERMINATED
Enrolment	1
Start date	Thu Jan 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed May 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced NSCLC

Interventions

• camrelizumab + famitinib
• famitinib
• docetaxel

Countries

China